Renal protective effects of oral Achillea millefolium in patients with type 2 diabetes: A double-blind, randomized, placebo-controlled trial

Background: Diabetic kidney disease is a highly prevalent and serious long-term complication of Type 2 Diabetes Mellitus (T2DM). Phytotherapeutic interventions are increasingly explored as adjunctive therapies. Achillea millefolium (AM), a traditional medicinal plant, has been postulated to possess renoprotective properties.Objectives: This study aimed to investigate the efficacy and renoprotective effects of AM supplementation on serum urea and creatinine levels in patients with T2DM as an adjunct therapy.Methods: In this double-blind, randomized, placebo-controlled trial (IRCT20230612058459N1), we enrolled 60 patients with T2DM. Participants were randomly assigned to receive either 500 mg/day of an AM capsule (n=30) or an identically appearing placebo (cellulose) capsule (n=30) for three months. Serum urea and creatinine concentrations were measured at baseline and after the intervention. Results: Following the three-month intervention, the AM group exhibited significant within-group reductions in both serum creatinine (from 1.17 ± 0.36 mg/dL to 0.84 ± 0.15 mg/dL; p < 0.0001) and serum urea (from 37.7 ± 10.02 mg/dL to 30.93 ± 6.12 mg/dL; p < 0.0001). In the placebo group, changes in these parameters were not statistically significant. However, the between-group analysis revealed that the post-intervention reductions in serum creatinine and urea in the AM group were not statistically significantly different from those observed in the placebo group (p = 0.117 and p = 0.221, respectively).Conclusion: Our results demonstrate that a three-month supplementation with 500 mg/day of AM significantly reduces serum creatinine and urea levels from baseline in patients with T2DM. However, the lack of a statistically significant between-group difference compared to placebo tempers the conclusion of efficacy, suggesting that the observed effect may not be attributable solely to the active intervention. Further large-scale studies are warranted to confirm these findings and elucidate the underlying mechanisms.

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-10-01
DOI
https://doi.org/10.22034/jpcm.2025.548936.1254
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Renal protective effects of oral Achillea millefolium in patients with type 2 diabetes: A double-blind, randomized, placebo-controlled trial

SHILAP Revista de lepidopterología
Natural Antidiabetic Agents Studies
article

Renal protective effects of oral Achillea millefolium in patients with type 2 diabetes: A double-blind, randomized, placebo-controlled trial

article en

Abstract

Background: Diabetic kidney disease is a highly prevalent and serious long-term complication of Type 2 Diabetes Mellitus (T2DM). Phytotherapeutic interventions are increasingly explored as adjunctive therapies. Achillea millefolium (AM), a traditional medicinal plant, has been postulated to possess renoprotective properties.Objectives: This study aimed to investigate the efficacy and renoprotective effects of AM supplementation on serum urea and creatinine levels in patients with T2DM as an adjunct therapy.Methods: In this double-blind, randomized, placebo-controlled trial (IRCT20230612058459N1), we enrolled 60 patients with T2DM. Participants were randomly assigned to receive either 500 mg/day of an AM capsule (n=30) or an identically appearing placebo (cellulose) capsule (n=30) for three months. Serum urea and creatinine concentrations were measured at baseline and after the intervention. Results: Following the three-month intervention, the AM group exhibited significant within-group reductions in both serum creatinine (from 1.17 ± 0.36 mg/dL to 0.84 ± 0.15 mg/dL; p < 0.0001) and serum urea (from 37.7 ± 10.02 mg/dL to 30.93 ± 6.12 mg/dL; p < 0.0001). In the placebo group, changes in these parameters were not statistically significant. However, the between-group analysis revealed that the post-intervention reductions in serum creatinine and urea in the AM group were not statistically significantly different from those observed in the placebo group (p = 0.117 and p = 0.221, respectively).Conclusion: Our results demonstrate that a three-month supplementation with 500 mg/day of AM significantly reduces serum creatinine and urea levels from baseline in patients with T2DM. However, the lack of a statistically significant between-group difference compared to placebo tempers the conclusion of efficacy, suggesting that the observed effect may not be attributable solely to the active intervention. Further large-scale studies are warranted to confirm these findings and elucidate the underlying mechanisms.

SHILAP Revista de lepidopterología
Shahrekord University of Medical Sciences (IR), Rafsanjan University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 38%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Renal protective effects of oral Achillea millefolium in patients with type 2 diabetes: A double-blind, randomized, placebo-controlled trial · SHILAP Revista de lepidopterología (2025) | TGRS Research Map | TGRS